Alzheimer's disease
JAS Lopez, HM González, GC Léger - Handbook of clinical neurology, 2019 - Elsevier
Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and
functional decline associated with age together with a particular neuropathology. It was first …
functional decline associated with age together with a particular neuropathology. It was first …
Dementia prevention, intervention, and care
Executive summary Acting now on dementia prevention, intervention, and care will vastly
improve living and dying for individuals with dementia and their families, and in doing so …
improve living and dying for individuals with dementia and their families, and in doing so …
Two randomized phase 3 studies of aducanumab in early Alzheimer's disease
S Budd Haeberlein, PS Aisen, F Barkhof… - The journal of …, 2022 - Springer
Background Alzheimer's disease is a progressive, irreversible, and fatal disease for which
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is …
accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is …
Aducanumab: appropriate use recommendations
Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …
Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial
Repetitive transcranial magnetic stimulation (rTMS) is emerging as a non-invasive
therapeutic strategy in the battle against Alzheimer's disease. Alzheimer's disease patients …
therapeutic strategy in the battle against Alzheimer's disease. Alzheimer's disease patients …
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study
Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's
disease, dementia with Lewy bodies, and multiple system atrophy. This provides an …
disease, dementia with Lewy bodies, and multiple system atrophy. This provides an …
Randomized trial of verubecestat for prodromal Alzheimer's disease
MF Egan, J Kost, T Voss, Y Mukai… - … England Journal of …, 2019 - Mass Medical Soc
Abstract Background Prodromal Alzheimer's disease offers an opportunity to test the effect of
drugs that modify the deposition of amyloid in the brain before the onset of dementia …
drugs that modify the deposition of amyloid in the brain before the onset of dementia …
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
MF Egan, J Kost, PN Tariot, PS Aisen… - … England Journal of …, 2018 - Mass Medical Soc
Background Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ)
plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor …
plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor …
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and–specific lesion patterns
Y Chen, M Dang, Z Zhang - Molecular Neurodegeneration, 2021 - Springer
Neuropsychiatric symptoms (NPSs) are common in patients with Alzheimer's disease (AD)
and are associated with accelerated cognitive impairment and earlier deaths. This review …
and are associated with accelerated cognitive impairment and earlier deaths. This review …
Effect of levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial
Importance Network hyperexcitability may contribute to cognitive dysfunction in patients with
Alzheimer disease (AD). Objective To determine the ability of the antiseizure drug …
Alzheimer disease (AD). Objective To determine the ability of the antiseizure drug …